Agios Pharmaceuticals : 40th Annual J.P. Morgan Healthcare Conference Presentation

Fueled by Connections

40th Annual J.P. Morgan Healthcare Conference January 12, 2022

1

Forward-looking statements

This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat and AG-946; Agios' plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including mitapivat and AG-946; Agios' strategic vision and goals, including its key milestones for 2022; Agios' plans regarding future data presentations; and the potential benefits of Agios' strategic plans and focus. The words "anticipate," "expect," "goal," "hope," "milestone," "plan," "potential," "possible," "strategy," "will," "vision," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this presentation

and various remarks we make during this presentation could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of the COVID-19 pandemic to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic and market conditions. These and other risks

are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward- looking statements contained in this presentation and various remarks we make during this presentation speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2

Cellular metabolism

drove our start 14

years ago.

We are fueled by

connections.

We are poised

to expand our impact.

AT-A-GLANCE
	1ST APPROVED		PK ACTIVATION PROGRAMS
FOUNDED	IPO	HEADQUARTERS	Pyruvate Kinase Deficiency
2008	July 2013	THERAPIES	Cambridge, Mass.	Thalassemia
2017 & 2018
3			Sickle Cell Disease

Strong
connections to
patients mean
we listen to and
work with them
to create
solutions	Tamara	Sharonda
	Pyruvate Kinase Deficiency	Sickle Cell Disease

Ryan

Thalassemia

4

Our strategy is anchored to our most differentiated capabilities and connectivity across research, clinical and commercial domains

Genetically

Defined Disease

Genetically defined disease is a broad umbrella that encompasses both rare and more common diseases

5

Genetically

Defined Disease

+

Cellular

Metabolism

Cellular

Metabolism

Cellular metabolism is a central part of our heritage and scientific competency